Looks like XEN which is widely considered underrated in the biotechnology sector is finally going to make it...
According to Suday Times "Two weeks ago, nine directors, including John Jackson, chairman, David Oxlade, chief executive, and Daniel Abrams, finance director, bought 304,670 shares between them at 25½p."
News of successful results from trials of vaccines for combating anal and genital cancer and rumours of more good news to follow...
With price up 4.75 (15.2%) to 36 on Friday breaking through a couple of resistance levels, chart started looking quite bullish...volume jumping to the highest level, RSI and Stochastics sharply ticking up, XEN certainly worth to watch as of monday
Riz
According to Suday Times "Two weeks ago, nine directors, including John Jackson, chairman, David Oxlade, chief executive, and Daniel Abrams, finance director, bought 304,670 shares between them at 25½p."
News of successful results from trials of vaccines for combating anal and genital cancer and rumours of more good news to follow...
With price up 4.75 (15.2%) to 36 on Friday breaking through a couple of resistance levels, chart started looking quite bullish...volume jumping to the highest level, RSI and Stochastics sharply ticking up, XEN certainly worth to watch as of monday
Riz